Greater China News
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
Exelixis, Inc. (Nasdaq: EXEL) and Insilico Medicine (“Insilico”) today announced that the companies have entered into an exclusive license agreement granting Exelixis global rights to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.
科律助力宜明昂科成功香港上市
宜明昂科生物医药技术（上海）股份有限公司（以下简称“宜明昂科”，股票代码：1541.HK）于今日在香港联合交易所主板正式挂牌上市。科律律师事务所（Cooley LLP）作为宜明昂科的国际律师，为公司的成功上市全程提供法律服务。
China to Set Up New Agency to Promote Private Sector Growth
China’s top economic planner is creating a new department to help private businesses, the latest step by the government to revive confidence in the sector and bolster growth.
Cantor Fitzgerald Bolsters Healthcare and Biotechnology Equity Research Team with Addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D.
Cantor Fitzgerald, L.P., ("Cantor") a leading global financial services firm, today announced the addition of Josh Schimmer, M.D., and Eric Schmidt, Ph.D., to its Healthcare and Biotechnology Research platform.
China: The latest medtech access policies and implications
In May 2023, NHSA indicated a change of direction from top-down management to a bottom-up approach, issuing policies requesting NRMDL to be established in all provinces by 2025.
Huadong to Buy Exclusive Rights for First-in-Class Skin Disease Drug in China
Huadong Medicine, one of China's most diversified makers of dermatosis medicines, will purchase exclusive rights for a first-in-class skin disease treatment developed by UK firm MC2 Therapeutics in China.
Neurophth Secures Australian Approval for Ophthalmic Gene Therapy
Neurophth Therapeutics (hereinafter referred to as "Neurophth"), a leader in in-vivo gene therapy for ophthalmic diseases in China, announced the Australian Therapeutic Goods Administration (TGA) has registered and approved its candidate drug, NFS-05, for clinical trials targeting Autosomal Dominant Optic Atrophy (ADOA).
AnHeart Therapeutics Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib for IDH1-Mutant Glioma
AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the first patient has been dosed in a Phase 2 clinical trial, G203, evaluating safusidenibin patients with Grades 2 or 3 recurrent or progressive mutant isocitrate dehydrogenase 1 (mIDH1) glioma, one of the most common types of adult primary brain cancer.
SIBIONICS Launches the Breakthrough SIBIO KS1 CKM for Ketone Level Monitoring
SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company's newest biometric wearable device designed to measure ketone levels
